- Trials with a EudraCT protocol (308)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (4)
308 result(s) found for: Cyclosporine A.
Displaying page 4 of 16.
EudraCT Number: 2017-004983-37 | Sponsor Protocol Number: FFIS-INM-2017-04 | Start Date*: 2018-10-16 |
Sponsor Name:Fundación para la Formación e Investigación Sanitarias de la Región de Murcia | ||
Full Title: Multicenter, randomized, prospective study to establish the clinical efficacy and the mechanisms of tolerance following immunosuppression withdrawal in liver transplantation | ||
Medical condition: Hepatic transplant | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-002726-23 | Sponsor Protocol Number: TMC435HPC3016 | Start Date*: 2013-12-12 | |||||||||||
Sponsor Name:Janssen R&D, Ireland | |||||||||||||
Full Title: Phase 2, Open-Label Study to Investigate the Pharmacokinetics, Efficacy, Safety, and Tolerability of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052) and Ribavirin (RBV) in Patients... | |||||||||||||
Medical condition: Hepatitis C Virus (HCV) genotype-1b Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004709-24 | Sponsor Protocol Number: CERL080ANL05 | Start Date*: 2007-03-20 | |||||||||||
Sponsor Name:ErasmusMC | |||||||||||||
Full Title: Mycophenolate sodium (Myfortic®) in the Treatment of Uveitis: a Pilot Study. | |||||||||||||
Medical condition: Uveitis | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005594-35 | Sponsor Protocol Number: TJB0603 | Start Date*: 2009-10-28 | |||||||||||
Sponsor Name:CHU Sart-Tilman | |||||||||||||
Full Title: Randomized double-blind study of mesenchymal stem cells (MSC) in patients undergoing matched unrelated allogeneic bone marrow or peripheral blood stem cell transplantation- A European multicentre s... | |||||||||||||
Medical condition: Hematological disorders of the following types: ALL: acute lymphoblastic leukemia in complete remission (<5% blasts in marrow) up to and including third remission (excluding relapse). AML: acute my... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004194-51 | Sponsor Protocol Number: 020520 | Start Date*: Information not available in EudraCT |
Sponsor Name:Medical University of Lodz | ||
Full Title: A prospective, randomized, phase III open-label clinical trial with blinded end-point assessment to evaluate the efficacy and safety of cyclosporine and methotrexate in children and adolescent subj... | ||
Medical condition: Atopic dermatitis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: PL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2011-002112-84 | Sponsor Protocol Number: CQGE031X2201 | Start Date*: 2011-11-29 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, placebo controlled, parallel group, proof of concept study evaluating the efficacy,safety, pharmacokinetics and pharmacodynamics of QGE031 in the treatment of patients w... | |||||||||||||
Medical condition: moderate to severe atopic dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DE (Prematurely Ended) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002974-48 | Sponsor Protocol Number: IM103-027 | Start Date*: 2005-11-17 |
Sponsor Name:Bristol-Myers Squibb International Corporation | ||
Full Title: Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - EXTended Criteria Donors (BENEFIT-EXT). Revised Protocol Number 03 incorporating Administrative Lett... | ||
Medical condition: TRANSPLANTATION, NOS | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) HU (Completed) AT (Completed) BE (Completed) SE (Completed) DE (Completed) CZ (Completed) IT (Completed) ES (Completed) PT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2004-003635-31 | Sponsor Protocol Number: IM103-008 | Start Date*: 2005-12-12 |
Sponsor Name:Bristol Myers Squibb International Corporation | ||
Full Title: Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial (BENEFIT). Revised Protocol 05 incorporating Protocol Amendments 13 (dated 10-Feb-2011) | ||
Medical condition: TRANSPLANTATION,NOS | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) BE (Completed) GB (Completed) CZ (Completed) IT (Completed) DE (Completed) ES (Completed) SE (Completed) HU (Completed) PT (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-004558-44 | Sponsor Protocol Number: 2021-00604 | Start Date*: 2021-10-10 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:UMCG | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Optimal Booster Strategy for SARS-CoV-2 Vaccination in Kidney Transplant patients | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: COVID-19 is associated with severely increased morbidity and mortality in kidney transplant patients. Available data show that the immune response after a standard regimen of two mRNA vaccinations ... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-003749-39 | Sponsor Protocol Number: NGF0221 | Start Date*: 2021-12-15 | |||||||||||
Sponsor Name:DOMPé FARMACEUTICI S.P.A. | |||||||||||||
Full Title: A 4 week, Phase III, multicenter, double-masked, vehicle-controlled study to evaluate safety and efficacy of Cenegermin (Oxervate®) 20 mcg/mL ophthalmic solution versus vehicle, in patients with s... | |||||||||||||
Medical condition: Severe Sjogren’s dry eye disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001212-30 | Sponsor Protocol Number: GW/MB/42964 | Start Date*: 2013-07-04 |
Sponsor Name: | ||
Full Title: Modulation of immune function by parenteral fish oil in patients with Crohn’s disease and high inherent Tumor Necrosis Factor-alfa production, a randomized, single blinded, cross-over study | ||
Medical condition: Crohn's disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000605-12 | Sponsor Protocol Number: notapplicable1 | Start Date*: 2014-06-13 |
Sponsor Name: | ||
Full Title: Thiazide diuretics versus calcium channel blockers for the treatment of calcineurin inhibitor-induced hypertension in patients with psoriasis or eczema: a single-center randomized cross-over trial. | ||
Medical condition: Hypertension, induced by the use of a Calcineurin Inhibitor (CNI) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-003689-32 | Sponsor Protocol Number: FARM5YZTZW | Start Date*: 2006-12-19 | |||||||||||
Sponsor Name:UNIVERSITA CAMPUS BIOMEDICO | |||||||||||||
Full Title: Multicenter, randomised, double masked, controlled studies on the efficacy of Cyclosporine eye drop treatment in preventing Vernal Keratoconjunctivitis VKC relapses and in treating the acute phase. | |||||||||||||
Medical condition: VERNAL KERATOCONJUNTIVITIS | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001352-13 | Sponsor Protocol Number: (ISA05-25) | Start Date*: 2006-09-27 |
Sponsor Name:Isotechnika Inc | ||
Full Title: A PHASE III, RANDOMIZED, MULTICENTRE, DOUBLE-BLIND, PLACEBO AND CYCLOSPORINE CONTROLLED STUDY OF ISA247 IN PLAQUE PSORIASIS PATIENTS (ISA05-25) | ||
Medical condition: Patient has stable, moderate to severe, plaque psoriasis over the previous 6 months; i.e., psoriasis must not be spontaneously improving or worsening in the 4 weeks prior to the screening visit. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001319-26 | Sponsor Protocol Number: FJD-COVID-ESTATINAS | Start Date*: 2020-05-14 |
Sponsor Name:Instituto de Investigación Sanitaria Fundación Jiménez Díaz | ||
Full Title: Multicenter, randomized, controlled, open-label clinical trial to assess the prognostic implications of rosuvastatin treatment in patients discharged after hospitalization for COVID-19 Positive. | ||
Medical condition: COVID respiratory infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004610-29 | Sponsor Protocol Number: 2014.001 | Start Date*: 2015-02-18 |
Sponsor Name:Skanes University Hospital | ||
Full Title: Ciclosporin to Protect Renal function In Cardiac Surgery. CiPRICS. A Phase II Double Blind Randomized Placebo Controlled Study. | ||
Medical condition: Renal dysfunction after CABG surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-012350-20 | Sponsor Protocol Number: MSC-KTx | Start Date*: 2008-01-14 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA "OSPEDALI RIUNITI DI BERGAMO" (A.O. DI RILIEVO NAZIONALE) | |||||||||||||
Full Title: MESENCHYMAL STEM CELLS UNDER BASILIXIMAB/ LOW DOSE RATG TO INDUCE RENAL TRANSPLANT TOLERANCE | |||||||||||||
Medical condition: Patients will be those receiving a living-related kidney transplant | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-014405-14 | Sponsor Protocol Number: VINODAT | Start Date*: 2009-08-27 |
Sponsor Name:Medizinische Universität Wien, Univ.Klinik Innere Medizin III, Abt.für Nephrologie u.Dialyse | ||
Full Title: Vildagliptin in New Onset Diabetes After Transplantation (ViNODAT). A double-blind, randomized, placebo-controlled trial | ||
Medical condition: new onset diabetes mellitus after transplantation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-006309-96 | Sponsor Protocol Number: 0881A6-3326 | Start Date*: 2007-06-08 |
Sponsor Name:Wyeth Pharmaceuticals France | ||
Full Title: A 3 Month, Randomised, Open Label, Parallel Group, Descriptive Study to Explore and Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept (Etanercept Autoinjecto... | ||
Medical condition: PSORIASIS | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) SE (Completed) NL (Completed) DK (Completed) BE (Completed) FI (Completed) ES (Completed) DE (Completed) GR (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-004231-37 | Sponsor Protocol Number: 1368-0013 | Start Date*: 2019-01-22 | |||||||||||
Sponsor Name:Boehringer Ingelheim France | |||||||||||||
Full Title: Multi-center, double-blind, randomised, placebo-controlled, Phase II study to evaluate efficacy, safety and tolerability of BI 655130 in patients with Generalized Pustular Psoriasis (GPP) presentin... | |||||||||||||
Medical condition: Generalized Pustular Psoriasis (GPP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
